MUC1 and neoplasm: The result showed that although treatment with the MUC1 vaccine or CTLA-4 siRNA-containing NLE could increase the number of CD8+ T cells infiltrating the tumor, the combination therapy was most effective in promoting the infiltration of CD8+ T cells compared to the individual treatments.